14 research outputs found
Incremental cost, effect, utility, and cost-effectiveness/cost-utility ratios from the societal perspective.
<p>Incremental cost, effect, utility, and cost-effectiveness/cost-utility ratios from the societal perspective.</p
Costs (total and disaggregated) and outcomes by treatment groups and study period.
<p>Costs (total and disaggregated) and outcomes by treatment groups and study period.</p
Unit costs used in the calculation of direct and indirect costs (financial year 2014; values in âŹ).
<p>Unit costs used in the calculation of direct and indirect costs (financial year 2014; values in âŹ).</p
Baseline sociodemographic characteristics of the patients by treatment group.
<p>Baseline sociodemographic characteristics of the patients by treatment group.</p
CONSORT flowchart of the participants in the economic evaluation.
<p>iTAU: improved treatment as usual; TSG: totally self-guided Internet-based program; LITG: low-intensity therapist-guided Internet-based program.</p
Cost-utility planes.
<p>Fig 2a. Scatterplot TSG vs. iTAU. Fig 2b. Scatterplot LITG vs. iTAU. QALY: quality-adjusted life year.</p
Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in the alcohol group according to alcohol-induced liver and pancreas diseases.
<p>(A) BDNF (pg/mL); (B) IGF-1 (ng/mL); and (C) IGFBP-3 (ÎŒg/mL) in alcohol group. Bars are the back-transformed means and 95% CI from logarithmic data. (*) p<0.05 denotes significant differences between the disease and no-disease subgroups.</p
Correlation analysis between age and plasma concentrations of IGF-1, BDNF and IGFBP-3.
<p>(A) IGF-1 (ng/mL) and age (years) in the total sample; (B) BDNF (pg/mL) and age (years) in the total sample; (C) IGFBP-3 (ÎŒg/mL) and age (years) in the total sample; (D) IGF-1 (ng/mL) and IGFBP-3 (ÎŒg/mL) in the total sample. Dots represent individual raw values. The Pearson correlation coefficient (r) and p-value are indicated for statistical significance. Note: One outlier value (4.313 pg/mL and 60 years old) was not represented.</p
Variables associated with AUD and psychiatric comorbidity in the alcohol group.
<p>Variables associated with AUD and psychiatric comorbidity in the alcohol group.</p
Plasma concentrations of BDNF, IGF-1 and IGFBP-3 in the alcohol and control groups.
<p>(A) BDNF (pg/mL); (B) IGF-1 (ng/mL); and (C) IGFBP-3 (ÎŒg/mL). Bars are the back-transformed means and 95% CI from logarithmic data. (***) p<0.001 denotes significant differences between the alcohol and control groups.</p